125 related articles for article (PubMed ID: 30924955)
1. Comparing Various In Vitro Prediction Methods to Assess the Potential of a Drug to Inhibit P-glycoprotein (P-gp) Transporter In Vivo.
Zhou T; Arya V; Zhang L
J Clin Pharmacol; 2019 Aug; 59(8):1049-1060. PubMed ID: 30924955
[TBL] [Abstract][Full Text] [Related]
2. Comparing Various In Vitro Prediction Criteria to Assess the Potential of a New Molecular Entity to Inhibit Organic Anion Transporting Polypeptide 1B1.
Vaidyanathan J; Yoshida K; Arya V; Zhang L
J Clin Pharmacol; 2016 Jul; 56 Suppl 7():S59-72. PubMed ID: 27385179
[TBL] [Abstract][Full Text] [Related]
3. Validation and application of Caco-2 assays for the in vitro evaluation of development candidate drugs as substrates or inhibitors of P-glycoprotein to support regulatory submissions.
Elsby R; Surry DD; Smith VN; Gray AJ
Xenobiotica; 2008 Jul; 38(7-8):1140-64. PubMed ID: 18668443
[TBL] [Abstract][Full Text] [Related]
4. In vitro predictability of drug-drug interaction likelihood of P-glycoprotein-mediated efflux of dabigatran etexilate based on [I]2/IC50 threshold.
Kishimoto W; Ishiguro N; Ludwig-Schwellinger E; Ebner T; Schaefer O
Drug Metab Dispos; 2014 Feb; 42(2):257-63. PubMed ID: 24212378
[TBL] [Abstract][Full Text] [Related]
5. Application of receiver operating characteristic analysis to refine the prediction of potential digoxin drug interactions.
Ellens H; Deng S; Coleman J; Bentz J; Taub ME; Ragueneau-Majlessi I; Chung SP; Herédi-Szabó K; Neuhoff S; Palm J; Balimane P; Zhang L; Jamei M; Hanna I; O'Connor M; Bednarczyk D; Forsgard M; Chu X; Funk C; Guo A; Hillgren KM; Li L; Pak AY; Perloff ES; Rajaraman G; Salphati L; Taur JS; Weitz D; Wortelboer HM; Xia CQ; Xiao G; Yamagata T; Lee CA
Drug Metab Dispos; 2013 Jul; 41(7):1367-74. PubMed ID: 23620486
[TBL] [Abstract][Full Text] [Related]
6. Commonly used surfactant, Tween 80, improves absorption of P-glycoprotein substrate, digoxin, in rats.
Zhang H; Yao M; Morrison RA; Chong S
Arch Pharm Res; 2003 Sep; 26(9):768-72. PubMed ID: 14560928
[TBL] [Abstract][Full Text] [Related]
7. Selection of an Optimal In Vitro Model to Assess P-gp Inhibition: Comparison of Vesicular and Bidirectional Transcellular Transport Inhibition Assays.
Yabut J; Houle R; Wang S; Liaw A; Katwaru R; Collier H; Hittle L; Chu X
Drug Metab Dispos; 2022 Jul; 50(7):909-922. PubMed ID: 35489778
[TBL] [Abstract][Full Text] [Related]
8. Development of Simplified in Vitro P-Glycoprotein Substrate Assay and in Silico Prediction Models To Evaluate Transport Potential of P-Glycoprotein.
Ohashi R; Watanabe R; Esaki T; Taniguchi T; Torimoto-Katori N; Watanabe T; Ogasawara Y; Takahashi T; Tsukimoto M; Mizuguchi K
Mol Pharm; 2019 May; 16(5):1851-1863. PubMed ID: 30933526
[TBL] [Abstract][Full Text] [Related]
9. Effects of Fostamatinib on the Pharmacokinetics of Digoxin (a P-Glycoprotein Substrate): Results From in Vitro and Phase I Clinical Studies.
Martin P; Gillen M; Millson D; Oliver S; Brealey C; Elsby R; Baluom M; Lau D; Mant T
Clin Ther; 2015 Dec; 37(12):2811-22. PubMed ID: 26514315
[TBL] [Abstract][Full Text] [Related]
10. Loxapine P-glycoprotein interactions in vitro.
Reed A; Huie K; Perloff ES; Cassella JV; Takahashi LH
Drug Metab Lett; 2012 Mar; 6(1):26-32. PubMed ID: 22300294
[TBL] [Abstract][Full Text] [Related]
11. Retrospective analysis of P-glycoprotein-mediated drug-drug interactions at the blood-brain barrier in humans.
Sugimoto H; Hirabayashi H; Amano N; Moriwaki T
Drug Metab Dispos; 2013 Apr; 41(4):683-8. PubMed ID: 23340958
[TBL] [Abstract][Full Text] [Related]
12. Drug-Drug Interactions of P-gp Substrates Unrelated to CYP Metabolism.
Akamine Y; Yasui-Furukori N; Uno T
Curr Drug Metab; 2019; 20(2):124-129. PubMed ID: 30280663
[TBL] [Abstract][Full Text] [Related]
13. Key Findings from Preclinical and Clinical Drug Interaction Studies Presented in New Drug and Biological License Applications Approved by the Food and Drug Administration in 2014.
Yu J; Ritchie TK; Zhou Z; Ragueneau-Majlessi I
Drug Metab Dispos; 2016 Jan; 44(1):83-101. PubMed ID: 26424199
[TBL] [Abstract][Full Text] [Related]
14. The utility of in vitro data in making accurate predictions of human P-glycoprotein-mediated drug-drug interactions: a case study for AZD5672.
Elsby R; Gillen M; Butters C; Imisson G; Sharma P; Smith V; Surry DD
Drug Metab Dispos; 2011 Feb; 39(2):275-82. PubMed ID: 21075975
[TBL] [Abstract][Full Text] [Related]
15. Predicting drug-drug interactions involving the inhibition of intestinal CYP3A4 and P-glycoprotein.
Tachibana T; Kato M; Takano J; Sugiyama Y
Curr Drug Metab; 2010 Nov; 11(9):762-77. PubMed ID: 21189139
[TBL] [Abstract][Full Text] [Related]
16. Blood-brain barrier (BBB) pharmacoproteomics: reconstruction of in vivo brain distribution of 11 P-glycoprotein substrates based on the BBB transporter protein concentration, in vitro intrinsic transport activity, and unbound fraction in plasma and brain in mice.
Uchida Y; Ohtsuki S; Kamiie J; Terasaki T
J Pharmacol Exp Ther; 2011 Nov; 339(2):579-88. PubMed ID: 21828264
[TBL] [Abstract][Full Text] [Related]
17. In Vitro-to-In Vivo Extrapolation of Transporter Inhibition Data for Drugs Approved by the US Food and Drug Administration in 2018.
Yu J; Ragueneau-Majlessi I
Clin Transl Sci; 2020 Jul; 13(4):693-699. PubMed ID: 31981398
[TBL] [Abstract][Full Text] [Related]
18. A regulatory viewpoint on transporter-based drug interactions.
Zhang L; Zhang YD; Strong JM; Reynolds KS; Huang SM
Xenobiotica; 2008 Jul; 38(7-8):709-24. PubMed ID: 18668428
[TBL] [Abstract][Full Text] [Related]
19. Effect of saquinavir/ritonavir on P-glycoprotein activity in healthy volunteers using digoxin as a probe.
Schmitt C; Kaeser B; Riek M; Bech N; Kreuzer C
Int J Clin Pharmacol Ther; 2010 Mar; 48(3):192-9. PubMed ID: 20197013
[TBL] [Abstract][Full Text] [Related]
20. Do differences in cell lines and methods used for calculation of IC
Volpe DA; Joshi A; Arya V
Xenobiotica; 2022 Jul; 52(7):751-757. PubMed ID: 36218364
[No Abstract] [Full Text] [Related]
[Next] [New Search]
